Wed, 7 Oct 2026
Markets
DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14% DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14%
The scariest thing about gray-market peptides is how little we know

The scariest thing about gray-market peptides is how little we know

This is Optimizer, a weekly newsletter sent from Verge senior reviewer Victoria Song that dissects and discusses the latest gizmos and potions that swear they're going to change your life. Opt in for Optimizer here. Finding concrete data about gray-market peptides is a Sisyphean task. Unlike bona fi...

The peptide wild west is hard to quantify. | Image: Cath Virginia / The Verge, Getty Images

This is Optimizer, a weekly newsletter sent from Verge senior reviewer Victoria Song that dissects and discusses the latest gizmos and potions that swear they're going to change your life. Opt in for Optimizer here.

Finding concrete data about gray-market peptides is a Sisyphean task. Unlike bona fide clinical drug trials, there are no official numbers. There's little to no safety data. Some peptides have more anecdotal evidence than others, but a stranger on r/peptides is, perhaps, not an ideal information source. The fact is most people partaking in a dubiously legal activity aren't going to shout it from the rooftops. What we do know abo …

Read the full story at The Verge.